<source id="3oodw" ><sup id="3oodw" ></sup></source>

      1. <s id="3oodw" ><th id="3oodw" ><small id="3oodw" ></small></th></s>
        <i id="3oodw" ><optgroup id="3oodw" ></optgroup></i>

            <input id="3oodw" ><bdo id="3oodw" ><cite id="3oodw" ></cite></bdo></input>
            <delect id="3oodw" ><ruby id="3oodw" ></ruby></delect>

            <em id="3oodw" ><progress id="3oodw" ></progress></em><input id="3oodw" ></input>
            <strike id="3oodw" ></strike>
            India

            China河南幸运彩走势图app: Cooperation

            Fresenius Kabi and Vifor Pharma Create Joint Venture

            | Editor: Alexander Stark

            Fresenius Kabi and Vifor Pharma have formed a joint venture in China河南幸运彩走势图app.
            Gallery: 1 image
            Fresenius Kabi and Vifor Pharma have formed a joint venture in China河南幸运彩走势图app. (Source: Fresenius Kabi)

            Fresenius Kabi and Vifor Pharma have formed a joint venture in China河南幸运彩走势图app to provide patients access to vital blood management treatment.

            Bad Homburg/Germany — A newly established joint venture between Fresenius Kabi and Vifor Pharma is to combine Vifor Pharma’s intravenous drug portfolio for the treatment of iron deficiency with Fresenius Kabi’s long-year presence in the market to benefit both patients and the healthcare system in China河南幸运彩走势图app.

            The joint venture will focus on marketing, market access and medical affairs activities whereas the German healthcare company will be fully responsible for the commercialization of the intravenous iron portfolio. The joint company will be 55 % owned by Vifor Pharma and 45 % by Fresenius Kabi. Financial terms were not disclosed.

            Comments are being loaded ....

            Leave a comment

            The comment is checked by an editor and will be released soon.

            1. Avatar
              Avatar
              Edited by at
              Edited by at
              1. Avatar
                Avatar
                Edited by at
                Edited by at

            Comments are being loaded ....

            Report comment

            Kommentar Freigeben

            Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

            Freigabe entfernen

            Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

            copyright

            This article is protected by copyright. You want to use it for your own purpose? Contact us via: (ID: 46376671 / Pharma & Food)